Literature DB >> 10218783

Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits.

J D Jentsch1, J R Taylor, J D Elsworth, D E Redmond, R H Roth.   

Abstract

Long-term exposure to the psychotomimetic drug phencyclidine produces prefrontal cortical cognitive and dopaminergic dysfunction in rats and monkeys, effects possibly relevant to the frontal cortical impairments of schizophrenia. In the present study, the effects of subchronic phencyclidine administration (0.3 mg/kg twice-daily for 14 days) on monoamine systems in the monkey brain were examined and related to cognitive performance on an object retrieval/detour task, which has been linked with frontostriatal function. Long-term (14 days) administration of phencyclidine resulted in a marked and persistent reduction in dopamine utilization in the frontal cortex. Moreover, the degree of cognitive impairment in phencyclidine-treated monkeys correlated significantly with the magnitude of dopaminergic inhibition within the dorsolateral prefrontal cortex and prelimbic cortex. No specific correlation was measured for dopamine utilization in other cortical regions or for indices of serotonin transmission in any brain region. These data show that repeated exposure to phencyclidine reduces prefrontal cortical dopamine transmission, and this inhibition of dopaminergic function is associated with performance impairments on a task sensitive to frontostriatal cognitive dysfunction. Thus, the cognitive deficits of phencyclidine-treated monkeys, as in schizophrenia, appear to be mediated, in part, by reduced dopaminergic function in specific subregions of the frontal cortex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218783     DOI: 10.1016/s0306-4522(98)00481-3

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  23 in total

1.  Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys.

Authors:  D M Lyons; J M Lopez; C Yang; A F Schatzberg
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Loss of asymmetric spine synapses in dorsolateral prefrontal cortex of cognitively impaired phencyclidine-treated monkeys.

Authors:  John D Elsworth; Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-27       Impact factor: 5.176

3.  Cognition-impairing effects of benzodiazepine-type drugs: role of GABAA receptor subtypes in an executive function task in rhesus monkeys.

Authors:  Leah Makaron; Casey A Moran; Ojas Namjoshi; Sundari Rallapalli; James M Cook; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

4.  Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia.

Authors:  Céline Risterucci; Karine Jeanneau; Stephanie Schöppenthau; Thomas Bielser; Basil Künnecke; Markus von Kienlin; Jean-Luc Moreau
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

Review 5.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

6.  The effects of AMPA receptor blockade in the prelimbic cortex on systemic and ventral tegmental area opiate reward sensitivity.

Authors:  Xavier De Jaeger; Stephanie F Bishop; Tasha Ahmad; Danika Lyons; Garye Ami Ng; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2012-09-13       Impact factor: 4.530

7.  Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment.

Authors:  K A Newell; K Zavitsanou; X-F Huang
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

8.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

Review 9.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

Review 10.  Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.

Authors:  Stacy A Castner; Patricia S Goldman-Rakic; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.